Amarantus Bioscience Holdings AMBS is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS wholly owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase b ready small molecule indicated for Parkinson s disease levodopa induced dyskinesia, Alzheimer s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program ESS , a regenerative medicine based approach for treating severe burns with full thickness autologous skin grown in tissue culture that is being pursued by AMBS wholly owned subsidiary Cutanogen Corporation. AMBS wholly owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte derived neurotrophic factor MANF . MANF Therapeutics, Inc. is developing MANF based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard. AMBS also owns approximately . million shares of Avant Diagnostics, Inc. via the sale of its wholly owned subsidiary Amarantus Diagnostics, Inc. that occurred in May .
Quote | Amarantus BioScience Holdings Inc (OTCMKTS:AMBS)
Last: | $1e-06 |
---|---|
Change Percent: | 0.0% |
Open: | $1e-06 |
Close: | $1e-06 |
High: | $0.0001 |
Low: | $1e-06 |
Volume: | 1,219,564 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Amarantus BioScience Holdings Inc (OTCMKTS:AMBS)
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
Message Board Posts | Amarantus BioScience Holdings Inc (OTCMKTS:AMBS)
Subject | By | Source | When |
---|---|---|---|
freegriff: Conclusions Substantially increased serum MANF concentrations after sTBI are highly corre | freegriff | investorshangout | 05/06/2023 2:21:06 AM |
freegriff: MANF stimulates autophagy and restores mitochondrial homeostasis to treat toxic proteinop | freegriff | investorshangout | 04/29/2023 5:58:32 AM |
freegriff: Gerald a little more active on linkedin lately. Talking to Psychogenics(eltoprazine) CEO | freegriff | investorshangout | 04/29/2023 2:45:55 AM |
freegriff: Colorado Voices: Ellie White https://youtu.be/XejfWrqgLO8 Clearly MANF still a research f | freegriff | investorshangout | 04/29/2023 12:35:27 AM |
GERALD failed CEO | JPetroInc | investorshub | 04/28/2023 1:17:06 AM |
News, Short Squeeze, Breakout and More Instantly...
Amarantus BioScience Holdings Inc Company Name:
AMBS Stock Symbol:
OTCMKTS Market:
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos e...